With the company actively buying back its stock and paying 3.5% yield, it's showing confidence in itself and putting money where its mouth is, making it worth the wait.
Huntington, which has bought back 32 million shares of its stock in the last 12 months, won't remain a secret forever.
U.S. Bancorp remains an underappreciated name despite being one of the best-managed banks.
BlackRock made a massive multi-billion dollar bet on Barclays' ETF assets. Check out how it's paid off and the ways investors will benefit.
Fifth Third is poised to become the best turnaround candidate in the banking sector.
Waiting for a lower price on a stock trading near its 52-week low is a strategy that could backfire.
With trading volumes back on the upswing, it's going to be a while before Goldman's money and generosity run dry.
Morgan Stanley has grown in market share in the trading business, and there's no sign that momentum is waning.
Bristol-Myers Squibb once showed interest in Shire. With AbbVie out of the way, could deal talks between Bristol-Myers and Shire resume? Here's why a Bristol-Myers and Shire deal makes sense.
Morgan Stanley's wealth management business is still making investors rich.